GHAPPcast

Thank you to Johnson & Johnson for your support of this Journal Club Video Module. In this video, Jamie Brogan, NP, from Northwestern Medicine in Chicago, discusses the efficacy and safety of Guselkumab therapy for patients with moderate to severely active Crohn’s disease, highlighting results from the Galaxy 2 and Galaxy 3 trials. Guselkumab is a dual-acting IL-23p19 subunit inhibitor, design...

In this video, Allison Moser, a transplant hepatology nurse practitioner at Rush University Medical Center, discusses the key principles of shared decision-making and how healthcare providers can better support their patients in making informed choices about their care. Shared decision-making is a collaborative approach that prioritizes communication, respect, and patient autonomy, ensuring that t...

Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this comprehensive medication review, Peter Byrne, FNP, from South Denver Gastroenterology, discusses the efficacy of guselkumab in treating ulcerative colitis (UC) and Crohn’s disease (CD) based on key clinical trials, including Quasar and Galaxy 1. Guselkumab has demonstrated significant efficacy in tr...

Sherona Bau, NP, at Pfleger Liver Institute, discusses the importance of providing effective care for patients with cirrhosis, which requires a proactive and comprehensive approach from healthcare providers, including physicians and advanced practice providers. Early diagnosis is crucial, as many patients with compensated cirrhosis remain asymptomatic. Using non-invasive testing, such as FibroScan...

Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this medication review module, Peter Byrne, FNP at South Denver Gastroenterology, discusses the safety of guselkumab in the treatment of Ulcerative Colitis and Crohn's disease. The Quasar trial, a phase 3 double-blind study, evaluated the safety of guselkumab in patients with inadequate responses to conv...

Thank you to Johnson & Johnson for your support of this Journal Club Video Module. In this Journal Club video module, Jamie Brogan, NP, from Northwestern, discusses findings from the Phase 2 GALAXI-1 Study, which evaluated guselkumab, a selective IL-23p19 antagonist, for the treatment of moderate-to-severe Crohn’s disease. This randomized, placebo-controlled study assessed intravenous guselkum...

In this episode of GHAPPcast, Jordan Mayberry, a PA-C at UT Southwestern in Dallas, Texas, and Patrick Horne, a nurse practitioner from the University of Florida, dive deep into the support strategies for healthcare providers and patients managing chronic liver disease and cirrhosis. As a healthcare provider, it’s essential to rely on a variety of resources to stay up-to-date on the latest guideli...

Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this video module, Amy Stewart, NP, from Capital Digestive Care, in Washington, D.C., explores the potential correlation between CD64-expressing myeloid cells and endoscopic disease severity in patients with inflammatory bowel disease (IBD). CD64 is a plasma membrane receptor found on myeloid cells, a category of bloo...

In this insightful GHAPPcast podcast, Patrick Horne, a nurse practitioner at the University of Florida, joins Jordan Mayberry, a physician assistant at UT Southwestern, to discuss the diagnosis and management of cirrhosis. They explore the latest diagnostic techniques, the role of non-invasive testing, and strategies for monitoring and managing cirrhosis patients to ensure the best possible care....

Thank you to Johnson & Johnson for your support of this FAQ Video Module. Join Sarah Enslin, PA-C, from the University of Rochester Medical Center, as she explores the latest advancements in CD64-positive cell targeting and IL-23-directed therapy. This innovative approach enhances the specificity and effectiveness of treatment for psoriasis, psoriatic arthritis, and inflammatory bowel disease...

In this GHAPP podcast episode, Jordan Mayberry, PA-C, and Patrick Horne, NP, dive deep into the complexities of chronic liver disease and its progression to cirrhosis. Drawing on over 11 years of experience in hepatology, Jordan and Patrick discuss the most common causes of liver disease, including viral hepatitis (Hepatitis B & C), alcohol-related liver disease, and metabolic-associated steat...

Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this medication review video module, Anne Feldman, NP, from the Cleveland Clinic Foundation, provides an in-depth overview of Guselkumab, an FDA-approved treatment for moderately to severely active ulcerative colitis. Anne explains the mechanism of action of Guselkumab, which is a dual-action monoclonal...

Thank you to Johnson & Johnson for your support of this GHAPPcast episode. In this insightful episode of GHAPPcast, the official podcast of the Gastroenterology and Hepatology Advanced Practice Providers, host Gabriella McCarty, NP-C, delves into the complex yet critical topic of CD64 positive binding and its relevance in inflammatory bowel disease (IBD) treatment, particularly in relation to...

Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this informative FAQ video module, Sarah Enslin, a physician assistant at the University of Rochester Medical Center, discusses the role of Interleukin-23 (IL-23) in treating immune-mediated inflammatory diseases, particularly inflammatory bowel disease (IBD). Sponsored by Johnson & Johnson, this video highlights...

Thank you to Johnson & Johnson for your support of this Journal Club Video Module. In this Journal Club video module, Shayla Scheonoff, a physician assistant from Rochester, Minnesota, provides a comprehensive review of the efficacy and safety of Guselkumab induction therapy for moderately to severely active ulcerative colitis (UC). Sponsored by Johnson & Johnson, this detailed analysis co...

Thank you to Johnson & Johnson for your support of this Medication Review Video Module. Clinical trials play a crucial role in guiding treatment decisions, but the way missing data is handled can significantly impact the results. In this medication review video module, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, NM, explains the concept of non-responder imputation (N...

Thank you to Johnson & Johnson for your support of this FAQ Video Module. Inflammatory Bowel Disease (IBD) is a complex condition influenced by genetic, environmental, and microbial factors. In this FAQ video module, Amy Stewart, ARNP, from Capital Digestive Care in Washington, DC, explains the critical role of the IL-23/IL-17 axis in the pathogenesis of IBD. Supported by Johnson & Johnson...

Thank you to Johnson & Johnson for your support of this FAQ Video Module. Welcome to this FAQ video module, proudly supported by Johnson & Johnson. In this educational session, Erica Heagy, NP, from Alaska Digestive and Liver Disease, explores the IL-23/IL-17 axis, a crucial pathway in the pathogenesis of inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, multiple sclerosis,...

Thank you to Johnson & Johnson for your support of this GHAPPcast episode. Welcome to GHAPPcast, the official podcast of Gastroenterology and Hepatology Advanced Practice Providers (GHAPP), where we delve into the latest advancements in GI and liver diseases. In this enlightening episode, host Gabriella McCarty, NP-C, from NorthShore Gastroenterology, explores the intricate role of the IL-23/I...

Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this medication review, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, New Mexico, explores the mechanism of action of Guselkumab, a promising monoclonal antibody therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). IBD is drive...

Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this FAQ video module, Erica Heagy, NP, from Alaska Digestive and Liver Disease, breaks down the key differences between humoral immunity and cell-mediated immunity, two crucial components of the adaptive immune system that protect the body from infections. Adaptive immunity is triggered when the body is exposed to an...

Live from the GHAPP National 2024 Conference, Dr. Dakesh Patel, a gastroenterologist with the GI Alliance of Illinois, joins Kate Scarlata, MPH, RD, a nationally renowned dietitian and bestselling author, and Kaitlin Colella, PA, to discuss congenital sucrase-isomaltase deficiency (CSID), a frequently overlooked digestive disorder. CSID affects the body's ability to break down sugar and starch due...

Welcome back to the final installment of our three-part miniseries on Primary Biliary Cholangitis (PBC) from the GHAPP National 2024 Conference! In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss the most impactful updates in PBC management, treatment goals, and evolving clinical strategies. A major highlight from this year’s meeting is the shifting treatment...

Welcome to Part 1 of our three-part miniseries on Primary Biliary Cholangitis (PBC), recorded live at GHAPP 2024! In this episode, Elizabeth Goacher, FNP (Duke University), Jeremy Davis, NP (Gastrointestinal Specialists, Louisiana), and Allison Moser, NP (Rush University Medical Center, Chicago) discuss the rising prevalence of PBC, increased awareness, and improved identification strategies in cl...

Welcome back to Part 2 of our three-part Primary Biliary Cholangitis (PBC) miniseries, where we explore the latest advancements in PBC treatment and disease management. In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss new therapeutic options, including seladelpar and elafibranor, and how these emerging treatments are transforming the PBC landscape. With the...